Chapter 9 294 71. Jason LA, Richman JA, Rademaker AW, et al. A Community-Based Study of Chronic Fatigue Syndrome. Archives of Internal Medicine 1999; 159(18): 2129-37. 72. Straub RH. The complex role of estrogens in inflammation. (0163-769X (Print)). 73. Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P. Long COVID risk - a signal to address sex hormones and women’s health. The Lancet Regional Health – Europe 2021; 11. 74. Schmidt C. The fight against non-communicable disease in emerging economies. Nature 2018. 75. Bigna JJ, Noubiap JJ. The rising burden of non-communicable diseases in sub-Saharan Africa. The Lancet Global Health 2019; 7(10): e1295-e6. 76. Chilunga FP, Appelman B, van Vugt M, et al. Differences in incidence, nature of symptoms, and duration of long COVID among hospitalised migrant and non-migrant patients in the Netherlands: a retrospective cohort study. The Lancet Regional Health - Europe 2023: 100630. 77. Richardson LJ, Brown TH. (En)gendering racial disparities in health trajectories: A life course and intersectional analysis. SSM - Population Health 2016; 2: 425-35. 78. Ailshire JA, House JS. The Unequal Burden of Weight Gain: An Intersectional Approach to Understanding Social Disparities in BMI Trajectories from 1986 to 2001/2002. Social Forces 2011; 90(2): 397-423. 79. Heise L, Greene ME, Opper N, et al. Gender inequality and restrictive gender norms: framing the challenges to health. The Lancet 2019; 393(10189): 2440-54. 80. Smyth NA-O, Alwan NA-O, Band R, et al. Exploring the lived experience of Long Covid in black and minority ethnic groups in the UK: Protocol for qualitative interviews and art-based methods. (1932-6203 (Electronic)). 81. Osikomaiya B, Erinoso OA-O, Wright KO, et al. ‘Long COVID’: persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. (1471-2334 (Electronic)). 82. Crankson SA-O, Pokhrel S, Anokye NK. Determinants of COVID-19-Related Length of Hospital Stays and Long COVID in Ghana: A Cross-Sectional Analysis. LID - 10.3390/ijerph19010527 [doi] LID - 527. (1660-4601 (Electronic)). 83. Lai Y-J, Liu S-H, Manachevakul S, Lee T-A, Kuo C-T, Bello D. Biomarkers in long COVID-19: A systematic review. Front Med (Lausanne) 2023; 10. 84. Schultheiß C, Willscher E, Paschold L, et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. (2666-3791 (Electronic)). 85. Potere N, Del Buono MG, Caricchio R, et al. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications. eBioMedicine 2022; 85. 86. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology 2023; 21(3): 133-46. 87. Strain WDS, Ondine; Banerjee, Amitava;van der Togt, Vicky; Hishmeh, Lyth; Rossman, Jeremy. The Impact of COVID Vaccination on Symptoms of Long COVID. An International Survey of People with Lived Experience of Long COVID. 2021. 88. Blomberg B, Mohn KG-I, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nature Medicine 2021; 27(9): 1607-13. 89. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. Journal of the Association of Medical Microbiology and Infectious Disease Canada 2020; 5(4): 223-34.
RkJQdWJsaXNoZXIy MTk4NDMw